Successful rescue treatment of sepsis due to a pandrug-resistant, NDM-producing Klebsiella pneumoniae using aztreonam powder for nebulizer solution as intravenous therapy in combination with ceftazidime/avibactam

Abstract

justifications for aztreonam dosing, then fT .MIC between 45% and 70% would seem appropriate. This is longer than the Gramnegative fT .MIC targets for cephalosporins of 30%-40% 7 and for carbapenems of 20%-35% 8 and more similar to that for penicillins of 30%-60%. 9 All the above data show the robustness of dilutional in vitro models in defining pharmacodynamic target sizes and their close alignment with animal models. Previous concerns about washout have also been shown to be baseless 10 and indeed dilutional models may be superior to hollow-fibre systems in terms of cost-effectiveness, biofilm formation and modelled drug concentrations.